TMCnet News
Research and Markets: Cancer Vaccines Drug Pipeline Update 2015 - 249 companies plus partners developing 280 cancer vaccine drugs in 630 developmental projectsResearch and Markets (http://www.researchandmarkets.com/research/rl52mx/cancer_vaccines) has announced the addition of the "Cancer Vaccines Drug Pipeline Update 2015" report to their offering. Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open. There are today 249 companies plus partners developing 280 cancer vaccine drugs in 630 developmental projects in cancer. In addition, there are8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 200 drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 182 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 150 out of the 153 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 45 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Pipeline Breakdown According to Number of Drugs
Delivery Format: Desktop App plus Online Access to Updates (One Year) For more information visit http://www.researchandmarkets.com/research/rl52mx/cancer_vaccines
|
